ArticleResearch and practice in thrombosis and haemostasis2025
External validation of the DAYS score for suspected deep vein thrombosis.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02486445 (Rivaroxaban for Scheduled Work-up of Patients With Suspected Deep Venous Thrombosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rivaroxaban for Scheduled Work-up of Patients With Suspected Deep Venous Thrombosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diagnosing deep vein thrombosis (DVT) involves clinical assessment, D-dimer testing, and imaging. The DAYS score, a novel 2-item prediction tool combined with D-dimer, demonstrated promising performance but required external validation. Objectives: This study aimed to validate 2 DVT prediction scores: the DAYS score and a newly developed DVT score. Methods: Data were collected from a prospective Norwegian DVT management study (2015-2018; NCT02486445). The DAYS score includes 2 items (DVT most likely diagnosis and calf swelling), while the new score comprises tenderness along the deep veins and previous venous thromboembolism. DVT was considered excluded if no items were present and D-dimer was < 1.0 μg/mL or if ≥1 item was present and D-dimer was < 0.5 μg/mL. The 2-tier Wells score served as the reference. Safety was defined as the number of missed DVT cases divided by the total number of patients classified as having DVT excluded and was set at 2%. Results: Among 1312 patients (median age, 64 years; IQR, 52-73 years; 55% women), 261 (20.0%) had confirmed DVT. The DAYS score excluded DVT in 455 patients (34.6%), of whom 11 were diagnosed with DVT (failure rate, 2.4 %; 95% CI, 1.2-4.2). The new score excluded DVT in 519 patients (39.6%) and missed 7 cases with confirmed DVT (failure rate, 1.3%; 95% CI, 0.5-2.8). The Wells score excluded DVT in 271 patients (20.6%), missing only 2 cases with confirmed DVT. Conclusion: While both the DAYS score and the new score demonstrated low failure rates, they exceeded the predefined safety threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.